A poster session at the 2015 San Francisco AAD meeting promotes the significant improvement in facial redness offered by the active called specific-kallikrein-5-regulator (SK5R). This ingredient is found a product called ROSÉLIANE Anti-Redness Cream, which is made by Uriage, who funded the trial that is described in the abstract presented.

It is interesting to see a topical being tested that claims to be able to address  cathelicidin LL-37 and kallikrein-5 (KLK5) expression, which is thought to lead to the inflammation associated with rosacea.

ROSÉLIANE Anti-Redness Cream Product Publicity

The product web site for ROSÉLIANE Anti-Redness Cream makes some claims about the active ingredients and the research behind them.

Restores and fortifies the immunological barrier

A new patent filed by the Uriage Dermatological Laboratories combines TLR2-Regul complex and SK5R complex (Specific-Kallikrein-5-Regulator) to regulate the activity of Kallikrein-5, a protease that causes inflammation and vascular problems, and provide highly effective soothing action.

ROSÉLIANE Anti-Redness Cream Ingredients

• Uriage Thermal Water
• Cerasterol-2F
• SK5R Complex
• TLR2-REGUL Complex
• Combination of plants
• Green pearlescent particles
• Glycerine
• Shea butter

AAD Poster Session

TLR-2, cathelicidin-LL37 and kallikrein-5 targeting in rosacea: In tubo, ex vivo and in vivo studies

JAAD Poster 1445, May 2015, Volume 72, Number 5, American Academy of Dermatology 73rd Annual Meeting, March 20-24, 2015, San Francisco, California.

Marius Anton Ionescu, MD, PhD, Dermatology Outpatient Clinic, University Hospital Saint Louis, Paris, France; Francine Joly, PhD, Sephrapharma, Puteaux, France; Elodie Bombard, PhD, Sephrapharma, Puteaux, France; Geraldine Robert, MBBCh, Laboratoires Dermatologiques d’Uriage, Neuilly sur Seine, France; Luc Lefeuvre, PharmD, Laboratoires Dermatologiques d’Uriage R&D, Neuilly sur Seine, France; Michel Bohbot, PharmD, PhD, Laboratoires Dermatologiques d’Uriage, Neuilly sur Seine, France

Background: Toll-like receptor 2 (TLR2) activation and antimicrobial peptides (AMP) up-regulation by Demodex species and by bacillus oleronius play an important role in rosacea physiopathology.

Post transductional changes of AMP cathelicidin LL-37 and kallikrein-5 (KLK5) expression lead to inflammation.

Objectives: To assess the inhibitor effect of specific-kallikrein-5-regulator (SK5R) on KLK5 in tubo, ex vivo, and in vivo in rosacea patients.

Materials and methods: In tubo assessment: enzymatic activity of KLK5 was assessed by incubating it with a chromogenic fluorescent substrate (Boc-Val-Pro-Arg). KLK5 inhibitor effect of the complex SK5R  (brown algae extract and Uriage thermal water) was assessed versus reference KLK inhibitor AEBSF.

• Ex vivo assessment: normal human skin explants – untreated or treated by an O/W emulsion based on SK5R – were put in contact with Demodex chitin fragments (of 40-70 “m, in suspension), control untreated explants had no contact with chitin. Dosage of IL-8 and KLK5 expression were made by ELISA.
• In vivo assessment: rosacea patients with no general or topical Rx were included in an open clinical trial using an O/W emulsion based on SK5R bid for 4 weeks. At baseline, week 2 (W2) and W4 were made: clinical examination, chromametry assessment of (parameter +a* – red in Lab* system) and photography. Scores were made for erythema, telangiectasias, roughness, sensations of ‘‘heat,’’ discomfort.

Results: In tubo: KLK5 was significantly decreased by AEBSF (by 98%) and by SK5R (by 68%).

• Ex vivo: in untreated explants in contact with Demodex chitin, both IL-8 and KLK5 were significantly increased compared to control (by 30% and respectively by 58%). In SK5R-treated explants in contact with chitin, the expression of KLK5 increased by 8% compared to control, IL-8 by 10%.
• In vivo: were included 40 female rosacea patients. The mean decrease of the chromametry parameter +a* was 9% at W4 compared to baseline. Skin roughness, diffuse facial erythema, discomfort and sensation of ‘‘heat’’ decreased significantly at W2 and W4.

Conclusions: In tubo tests showed an inhibition kallikrein-5, ex vivo study on SK5R- treated human skin in contact with Demodex chitin showed a decrease of kallikrein-5. In a clinical trial on 40 rosacea patients, an O/W emulsion based on SK5R applied bid for 4 weeks significantly improved facial erythema and rosacea symptoms.

Study Funded by Laboratoires Dermatologiques d’Uriage.

Featured Products

Related Articles

• Uriage Thermal Water for a Red Face (2012 AAD San Diego)
• Just how does Finacea work ?
• Bradykinin and Neurogenic Inflamation – a possible aetiology ?
• Focus on cathelicidin and its role in rosacea
• Gallo to trial Aminocaproic Acid as Cathelicidin Inhibitor
• Doxycycline can deactivate Cathelicidins